Global markets have been buoyed by optimism surrounding a potential U.S.-Iran peace agreement, with major U.S. stock indexes like the Nasdaq Composite and Russell 2000 reaching record highs, driven in part by enthusiasm for AI-linked stocks. In this environment of rising investor sentiment and technological momentum, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on advancements in artificial intelligence and other innovative technologies.
Here’s a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: ABIVAX Société Anonyme is a clinical-stage biotechnology company focused on developing therapeutics to stabilize the immune response in chronic inflammatory diseases, with a market cap of €6.69 billion.
Operations: ABIVAX Société Anonyme focuses on the research and development of pharmaceutical products, generating revenue primarily from this segment. The company operates within the biotechnology sector, emphasizing immune response stabilization in chronic inflammatory conditions.
Amidst a challenging backdrop, ABIVAX Société Anonyme has shown promising developments in its biotechnological pursuits, notably with obefazimod for ulcerative colitis. The company’s recent Phase 3 trial results underscore its potential in the biotech sector, showing significant efficacy in maintaining clinical remission compared to placebos. Despite a volatile share price and ongoing unprofitability, revenue growth projections at 59% annually surpass the French market’s average. With R&D expenses aligning closely with these ambitious projects, ABIVAX is strategically positioning itself for profitability within three years, suggesting a robust pipeline that could alter treatment paradigms in immunology-based therapies.
ENXTPA:ABVX Earnings and Revenue Growth as at Jun 2026
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Jinyu Bio-technology Co., Ltd. focuses on the manufacturing and sales of veterinary biological drugs in China, with a market cap of CN¥12.46 billion.
Operations: The company specializes in producing veterinary biological drugs, generating revenue primarily from domestic sales within China. It operates with a market capitalization of CN¥12.46 billion.
Jinyu Bio-technology’s recent financial performance showcases its resilience and potential in the biotech sector, with a notable first-quarter revenue of CNY 346.46 million and an increase in net income to CNY 80.64 million from the previous year. The company is making significant strides, evidenced by a robust annual earnings growth forecast of 44.2%, surpassing the Chinese market’s average growth rate. Moreover, Jinyu Bio-technology continues to invest heavily in research and development, aligning its strategy with industry demands and future growth prospects, which is crucial for maintaining its competitive edge in a rapidly evolving sector. This commitment to innovation is likely to sustain its upward trajectory amidst intense market competition.
SHSE:600201 Revenue and Expenses Breakdown as at Jun 2026
Simply Wall St Growth Rating: ★★★★★★
Overview: Shennan Circuits Co., Ltd. specializes in the design, manufacture, and sale of printed circuit boards, packaging substrates, and electronic assemblies both in China and internationally, with a market cap of CN¥267.96 billion.
Operations: The company focuses on producing printed circuit boards, packaging substrates, and electronic assemblies for both domestic and international markets. It operates with a market capitalization of CN¥267.96 billion.
Shennan Circuits has demonstrated a robust financial trajectory, with first-quarter sales soaring to CNY 6.6 billion from CNY 4.8 billion year-over-year, and net income nearly doubling to CNY 850.23 million. This growth is underpinned by a significant R&D commitment, which is crucial as the firm navigates the competitive tech landscape marked by rapid innovation cycles. The company’s recent dividend increase also reflects its strong cash flow position, supporting its capability to reinvest in technology and expand market share amidst dynamic industry demands.
SZSE:002916 Revenue and Expenses Breakdown as at Jun 2026
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Searching for a Fresh Perspective?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTPA:ABVX SHSE:600201 and SZSE:002916.
